Oricell Biotech has successfully raised $110 million to advance its carcinoma CAR-T therapy plans, with an IPO push on the horizon. This funding round highlights the growing interest in innovative cancer therapies and the potential for CROs to engage in early-phase bioanalysis and CMC activities. The influx of capital could accelerate Oricell’s development timelines, necessitating efficient project management and regulatory navigation to meet market demands.
Source: Fierce Biotech ↗